SCHEMBL18337160

SCHEMBL18337160

CC(C)(C)OC(=O)N1CC[C@H](NC(=O)OCc2ccccc2)[C@@H]1C(=O)NCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB1 P15086 2/20 0.45
HTT P42858 1/20 0.44
HDAC8 Q9BY41 1/20 0.43
FKBP1A P62942 1/20 0.42
ABCB1 P08183 1/20 0.42
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 1/20 0.41
ALDH1A1 P00352 2/20 0.41
STS P08842 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
CTSL P07711 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18337016 1.00 CPB1 (0.45) CPB1HTTHDAC8FKBP1AABCB1
SCHEMBL31058400 0.89 ALDH1A1 (0.47) CPB1HTTABCB1NPC1RAB9A
SCHEMBL14468657 0.89 ALDH1A1 (0.47) CPB1HTTABCB1NPC1RAB9A
SCHEMBL5941341 0.89 ALDH1A1 (0.47) CPB1HTTABCB1NPC1RAB9A
SCHEMBL4040280 0.89 ALDH1A1 (0.47) CPB1HTTABCB1NPC1RAB9A
SCHEMBL18337377 0.88 CPB1 (0.48) CPB1HTTFKBP1AABCB1NPC1
SCHEMBL25907340 0.87 CPB1 (0.53) CPB1HTTFKBP1AABCB1NPC1
SCHEMBL32672364 0.87 CPB1 (0.53) CPB1HTTFKBP1AABCB1NPC1
SCHEMBL6347376 0.85 CPB1 (0.46) CPB1HTTFKBP1AABCB1LMNA
SCHEMBL18335958 0.85 CPB1 (0.46) CPB1HTTFKBP1AABCB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3683222-B1 NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2021-10-06 EP disclosed
EP-3683222-A1 NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2020-07-22 EP disclosed
US-10065972-B2 Bicyclic or tricyclic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2018-09-04 US disclosed
EP-3135674-A1 NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2017-03-01 EP disclosed
US-20160376289-A1 NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160376289-A1 NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND CBR3, CBR1, CYCS CPB1 2213/4885HTT 3393/4885HDAC8 649/4885
US-10065972-B2 Bicyclic or tricyclic heterocyclic compound CBR3, CBR1, CYCS CPB1 2226/4885HTT 2879/4885HDAC8 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.